<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Raj SKS</submitter><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>Comprehensive Cancer Center at Wake Forest Baptist Medical Center</funding><pagination>3254-3264</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9544607</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>128(17)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Cellular and intrinsic markers of sarcoma immunogenicity are poorly understood. To gain insight into whether tumor-immune interactions correlate with clinical aggressiveness, the authors examined the prognostic significance of immune gene signatures in combination with tumor mutational burden (TMB) and cancer-testis antigen (CTA) expression.&lt;h4>Methods&lt;/h4>RNA sequencing and clinical data of 259 soft tissue sarcomas from The Cancer Genome Atlas project were used to investigate associations between published immune gene signatures and patient overall survival (OS) in the contexts of TMB, as computed from whole-exome sequencing data, and CTA gene expression. Multivariate Cox proportional hazards regression models and log-rank tests were used to assess survival associations</pubmed_abstract><journal>Cancer</journal><pubmed_title>Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.</pubmed_title><pmcid>PMC9544607</pmcid><funding_grant_id>P30 CA012197</funding_grant_id><funding_grant_id>P30CA012197</funding_grant_id><pubmed_authors>Chou JW</pubmed_authors><pubmed_authors>Votanopoulos KI</pubmed_authors><pubmed_authors>Raj SKS</pubmed_authors><pubmed_authors>Routh ED</pubmed_authors><pubmed_authors>Triozzi PL</pubmed_authors><pubmed_authors>Miller LD</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.</name><description>&lt;h4>Background&lt;/h4>Cellular and intrinsic markers of sarcoma immunogenicity are poorly understood. To gain insight into whether tumor-immune interactions correlate with clinical aggressiveness, the authors examined the prognostic significance of immune gene signatures in combination with tumor mutational burden (TMB) and cancer-testis antigen (CTA) expression.&lt;h4>Methods&lt;/h4>RNA sequencing and clinical data of 259 soft tissue sarcomas from The Cancer Genome Atlas project were used to investigate associations between published immune gene signatures and patient overall survival (OS) in the contexts of TMB, as computed from whole-exome sequencing data, and CTA gene expression. Multivariate Cox proportional hazards regression models and log-rank tests were used to assess survival associations</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-04-22T12:06:27.402Z</modification><creation>2025-04-06T00:14:53.092Z</creation></dates><accession>S-EPMC9544607</accession><cross_references><pubmed>35767280</pubmed><doi>10.1002/cncr.34333</doi></cross_references></HashMap>